RNA Barcode Biopsy Advances Precision Oncology: New Blood Test Could Guide Cancer Treatment

Researchers are advancing a new type of liquid biopsy that analyzes RNA in the bloodstream to detect cancer and monitor treatment resistance, offering a potential advance in precision oncology. This approach, referred to as a “bar code” biopsy, focuses on cell-free RNA fragments released by cells, including tumors, into the bloodstream. By examining these molecular remnants, scientists aim to identify cancer at various stages, track how tumors evolve in response to therapy, and assess damage to healthy tissue caused by both cancer and non-cancerous conditions.

The method builds on the understanding that dying cells release genetic material into circulation, creating a molecular record of cellular activity. While traditional liquid biopsies primarily analyze cell-free DNA, researchers note that RNA provides additional layers of information, particularly about gene expression and cellular responses to stress or treatment. This distinction may allow the test to capture dynamic changes in tumor behavior that DNA-based methods might miss, especially in early-stage disease or during therapeutic resistance.